View of Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

Return to Issue Details Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity) Download Download PDF